Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria
Open Access
- 5 April 2024
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (15)
Abstract
Here, we describe the identification of an antibiotic class acting via LpxH, a clinically unexploited target in lipopolysaccharide synthesis. The lipopolysaccharide synthesis pathway is essential in most Gram-negative bacteria and there is no analogous pathway in humans. Based on a series of phenotypic screens, we identified a hit targeting this pathway that had activity on efflux-defective strains of Escherichia coli . We recognized common structural elements between this hit and a previously published inhibitor, also with activity against efflux-deficient bacteria. With the help of X-ray structures, this information was used to design inhibitors with activity on efflux-proficient, wild-type strains. Optimization of properties such as solubility, metabolic stability and serum protein binding resulted in compounds having potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae . Other favorable properties of the series include a lack of pre-existing resistance in clinical isolates, and no loss of activity against strains expressing extended-spectrum-β-lactamase, metallo-β-lactamase, or carbapenemase-resistance genes. Further development of this class of antibiotics could make an important contribution to the ongoing struggle against antibiotic resistance.Keywords
Funding Information
- Innovative Medicines Initiative Joint Undertaking (115583)
- Swedish Research Council (Dnr 2021-06603)
This publication has 37 references indexed in Scilit:
- Development of LpxH Inhibitors Chelating the Active Site Dimanganese Metal Cluster of LpxHChemMedChem, 2023
- Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectivesEuropean Journal of Medicinal Chemistry, 2023
- Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort studyIntensive Care Medicine, 2023
- Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative BacteriaAccounts of Chemical Research, 2021
- Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External StressesJournal of Medicinal Chemistry, 2021
- Synthesis and evaluation of sulfonyl piperazine LpxH inhibitorsBioorganic Chemistry, 2020
- Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular SafetyChemMedChem, 2019
- Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal SiteMolecular Cell, 2018
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisThe Lancet Infectious Diseases, 2018
- PubChem: Integrated Platform of Small Molecules and Biological Activities2008